Oryzon Genomics SA (ORY) - Total Liabilities

Latest as of December 2025: €26.68 Million EUR ≈ $31.19 Million USD

Based on the latest financial reports, Oryzon Genomics SA (ORY) has total liabilities worth €26.68 Million EUR (≈ $31.19 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Oryzon Genomics SA cash flow conversion to assess how effectively this company generates cash.

Oryzon Genomics SA - Total Liabilities Trend (2011–2025)

This chart illustrates how Oryzon Genomics SA's total liabilities have evolved over time, based on quarterly financial data. Check ORY asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Oryzon Genomics SA Competitors by Total Liabilities

The table below lists competitors of Oryzon Genomics SA ranked by their total liabilities.

Company	Country	Total Liabilities
Indoco Remedies Limited NSE:INDOCO	India	Rs15.34 Billion
BINEX Co. Ltd KQ:053030	Korea	₩117.14 Billion
Korea Real Estate Investment & Trust Co Ltd KO:034830	Korea	₩899.23 Billion
C&F Financial Corporation NASDAQ:CFFI	USA	$2.46 Billion
Stille AB ST:STIL	Sweden	Skr362.30 Million
NXG NextGen Infrastructure Income Fund NYSE:NXG	USA	$54.45 Million
BAJEL PROJECTS LTD NSE:BAJEL	India	Rs12.88 Billion
Chung Hwa Food Industrial Co Ltd TWO:4205	Taiwan	NT$424.65 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Oryzon Genomics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ORY stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.95	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.25	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.18	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Oryzon Genomics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Oryzon Genomics SA (2011–2025)

The table below shows the annual total liabilities of Oryzon Genomics SA from 2011 to 2025.

Year	Total Liabilities	Change
2025-12-31	€26.68 Million ≈ $31.19 Million	+23.07%
2024-12-31	€21.67 Million ≈ $25.34 Million	-13.74%
2023-12-31	€25.13 Million ≈ $29.37 Million	-19.28%
2022-12-31	€31.13 Million ≈ $36.39 Million	+29.04%
2021-12-31	€24.12 Million ≈ $28.20 Million	+32.72%
2020-12-31	€18.18 Million ≈ $21.25 Million	+22797.11%
2019-12-31	€79.38K ≈ $92.80K	-99.64%
2018-12-31	€22.33 Million ≈ $26.10 Million	-16.11%
2017-12-31	€26.61 Million ≈ $31.11 Million	-1.49%
2016-12-31	€27.02 Million ≈ $31.58 Million	+105.63%
2015-12-31	€13.14 Million ≈ $15.36 Million	+8.00%
2014-12-31	€12.16 Million ≈ $14.22 Million	-13.32%
2013-12-31	€14.04 Million ≈ $16.41 Million	+13.63%
2012-12-31	€12.35 Million ≈ $14.44 Million	-0.81%
2011-12-31	€12.45 Million ≈ $14.56 Million	--

About Oryzon Genomics SA

MC:ORY Spain Biotechnology

Market Cap

$249.57 Million

€213.47 Million EUR

Market Cap Rank

#16083 Global

#103 in Spain

Share Price

€2.75

Change (1 day)

+0.29%

52-Week Range

€2.57 - €3.82

All Time High

€5.14